Emilie Indersie

Evry, 91000, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications

Preclinical Drug-Response Profiling Identifies BMI1 Inhibition as a Therapeutic Option for Hepatoblastoma.

Preclinical Drug-Response Profiling Identifies BMI1 Inhibition as a Therapeutic Option for Hepatoblastoma.

Journal: International journal of molecular sciences
Published: April 17, 2026

Proteasome Targeting with Carfilzomib Induces Reactive Oxygen Species-Mediated Apoptosis in Hepatoblastoma.

Proteasome Targeting with Carfilzomib Induces Reactive Oxygen Species-Mediated Apoptosis in Hepatoblastoma.

Journal: Cells
Published: March 25, 2026

The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers.

The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers.

Journal: Cancer research
Published: November 19, 2025

Ex vivo drug sensitivity profiling to complement molecular profiling in pediatric precision oncology.

Ex vivo drug sensitivity profiling to complement molecular profiling in pediatric precision oncology.

Journal: NPJ precision oncology
Published: July 23, 2025

Ex vivo drug sensitivity profiling to complement molecular profiling in pediatric precision oncology.

Ex vivo drug sensitivity profiling to complement molecular profiling in pediatric precision oncology.

Journal: NPJ precision oncology
Published: July 23, 2025

Mechanistic models position ceritinib as a nuclear integrity disrupting therapy in pediatric liver tumors.

Mechanistic models position ceritinib as a nuclear integrity disrupting therapy in pediatric liver tumors.

Journal: Journal of experimental & clinical cancer research : CR
Published: May 28, 2025

Targeting HSP90 with Ganetespib to Induce CDK1 Degradation and Promote Cell Death in Hepatoblastoma.

Targeting HSP90 with Ganetespib to Induce CDK1 Degradation and Promote Cell Death in Hepatoblastoma.

Journal: Cancers
Published: March 20, 2025

GATA4-targeted compounds induce apoptosis and diminish viability of hepatoblastoma cells.

GATA4-targeted compounds induce apoptosis and diminish viability of hepatoblastoma cells.

Journal: PloS one
Published: March 06, 2025

Multiomic integration reveals tumoral heterogeneity of lipid dependence within lethal group 3 medulloblastoma.

Multiomic integration reveals tumoral heterogeneity of lipid dependence within lethal group 3 medulloblastoma.

Journal: Cancer cell
Published: January 16, 2025

Drug prioritization identifies panobinostat as a tailored treatment element for patients with metastatic hepatoblastoma.

Drug prioritization identifies panobinostat as a tailored treatment element for patients with metastatic hepatoblastoma.

Journal: Journal of experimental & clinical cancer research : CR
Published: August 28, 2024

Functional screening identifies kinesin spindle protein inhibitor filanesib as a potential treatment option for hepatoblastoma.

Functional screening identifies kinesin spindle protein inhibitor filanesib as a potential treatment option for hepatoblastoma.

Journal: NPJ precision oncology
Published: August 06, 2024

EZH2 is a key prognostic marker and therapeutic target in aggressive and proliferative hepatoblastoma.

EZH2 is a key prognostic marker and therapeutic target in aggressive and proliferative hepatoblastoma.

Journal: Molecular cancer
Published: May 03, 2024
Showing 1-12 of 24

Last Updated: 09/26/2026